Under DRGs mode, how should drug companies deal with anxiety?

[industry trends of pharmaceutical network] just entering 2020, the National Health Commission, medical administration and medical administration issued a very important notice to the medical field: Notice on printing and distributing the clinical pathway of diseases (2019 version) According to the notice, according to the clinical practice and combined with the medical progress, the national health and Health Commission has organized the revision of the clinical pathway of 19 subjects related to diseases, forming 224 clinical pathways of diseases (2019 version)
It is understood that the clinical pathway is based on evidence-based medicine, aiming at a disease or operation with clear diagnosis, aiming at the expected treatment effect and cost control, in order to facilitate the medical staff to carry out the treatment plan in a planned way, reduce the variables in the clinical treatment process, and ensure the smooth implementation of the treatment plan It has strict work order and accurate time requirements Procedural and standardized medical examination and disposal process The clinical pathway is not static, but continuously improved with the accumulation of evidence-based medicine, the development and application of health technology, the promotion of medical needs, and the norms of diagnosis and treatment behavior In addition, the development of clinical pathway is closely related to the reform of payment system The reform of payment system promotes the implementation of clinical pathway in medical institutions to improve internal management The implementation of clinical pathway not only ensures that hospitals can maintain the benefits under the new policy environment, but also ensures the treatment effect In addition, it can effectively buffer the shock brought by policy change Because this is closely related to the payment system reform, we have to mention the DRGs payment system which plays an increasingly important role in the payment system reform of the whole medical industry In fact, in recent years, in addition to the 4 + 7 volume procurement, the discussion about DRGs should be the focus of the industry As early as October 16, 2019, the National Medical Security Bureau officially issued the notice on printing and distributing the technical specifications and grouping schemes of DRG paid country pilot, which contains two important standards, namely, the technical specifications for DRG grouping and payment of national medical security and the grouping scheme of national medical security DRG (chs-drg) This means that DRG core standards have been introduced, which will bring not only the payment reform of medical institutions, but also the reshuffle of the whole medical industry in the future In short, if the medical insurance bureau makes a breakthrough in reducing the drug price and controlling the medical insurance cost through the way of purchasing with quantity, DRGs is to change the medical behavior, reduce the proportion of irrational drugs, promote the pharmaceutical enterprises to improve the product value, so as to achieve the goal of sustainable medical insurance cost For pharmaceutical companies, whether the next product can enter the DRG payment group of corresponding diseases has become a key action to determine the fate of the product to some extent But obviously, with the two new standards issued by the state health insurance bureau, the window period for pharmaceutical enterprises to change their business ideas and product structure to meet the requirements of the new market in the future has been very short! In the future, if the pharmaceutical enterprises want to develop more smoothly, they should turn from benefit driven to thinking about the clinical value of products, so as to change the thinking of product research and development There is no doubt that the enterprises with obvious cost advantage and strong research and development ability will go further in this unknown war